Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Peptide-siRNA Conjugate

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Dec 14, 2021 12:00pm

210 Views

Post# 34229219

RE:Peptide-siRNA Conjugate

I imagine if the phase 1a shows proof of concept that there could be an explsion of interest in the Sort1+ platform from other pharma companies. Clearly, some are already interested based on what TH has indicated but if TH-1902 does successfully deliver the payload and bypass the cancer cell's defense mechanisms, the focus on TH as a partner will almost certainly get exciting pretty fast.

scarlet1967 wrote:

Recall Paul mentioned using their targeted delivery technology for siRNA.

“One of the most important advances in biology has been the discovery that siRNA small interfering RNA is able to regulate the expression of genes, by a phenomenon known as RNAi.”

It seems like that is a huge opportunity by itself.

For instance in cancer they target genes encoding the key proteins responsible for growth of cancer cells and vascular endothelial growth factor so the cancer either stabilized after six months, or regression of metastasis in some of the patients. The challenge for siRNA is intracellular delivery so that’s where endocytosis-mediated cell entry make a huge difference as for getting siRNA to targeted cells.

“Peptide-siRNA conjugate

The peptide-siRNA conjugate of BOC RNA is considered a potent drug delivery strategy since the short cell-penetrating peptide (CPP) is capable of carrying cargo into the cells owing to its easy penetration through the cell membranes. BOC RNA, working with its parent company BOC Sciences, builds a siRNA drug delivery platform that offers the design and synthesis of siRNA, high-quality peptides, as well as peptide-siRNA conjugates. Equipped with advanced technology, BOC RNA has been providing professional technical support for peptide-siRNA conjugation in the last few years.”

Read more: https://www.digitaljournal.com/pr/sirna-drug-delivery-platform-of-boc-rna-speeds-up-disease-treatment-research#ixzz7EyVGu7As

https://rna.bocsci.com/products-services/peptide-sirna-conjugates.html